Pfizer Says Next-Generation Pneumococcal Vaccine Showed Stronger Immune Response in Infant Study

MT Newswires Live05-20 17:37

Pfizer (PFE) said Wednesday that its experimental 25-valent pneumococcal vaccine generated stronger immune responses than the company's currently approved PREVNAR 20 in a mid-stage infant study.

Preliminary phase 2 data showed antibody levels against serotype 3, a major remaining cause of pneumococcal disease in children, were significantly higher in infants receiving Pfizer's investigational vaccine candidate, 25vPnC, compared with Prevnar 20 after both the third and fourth doses, Pfizer said.

Pfizer said the vaccine candidate could potentially cover up to 90% of disease-causing pneumococcal serotypes in children under five years old.

The company said it has already started a pivotal pediatric phase 3 trial evaluating the vaccine in up to 2,400 healthy children.

Pfizer said it plans to move directly to a fifth-generation adult pneumococcal vaccine candidate covering 35 serotypes, which it expects to enter clinical development by the end of 2026.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2636810748?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-20 17:37","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2636810748","market":"nz","top_or_hot":-1,"title":"Pfizer Says Next-Generation Pneumococcal Vaccine Showed Stronger Immune Response in Infant Study","media":"MT Newswires Live","content":"<html><body><p> Pfizer (PFE) said Wednesday that its experimental 25-valent pneumococcal vaccine generated stronger immune responses than the company's currently approved PREVNAR 20 in a mid-stage infant study.</p><p>Preliminary phase 2 data showed antibody levels against serotype 3, a major remaining cause of pneumococcal disease in children, were significantly higher in infants receiving Pfizer's investigational vaccine candidate, 25vPnC, compared with Prevnar 20 after both the third and fourth doses, Pfizer said.</p><p>Pfizer said the vaccine candidate could potentially cover up to 90% of disease-causing pneumococcal serotypes in children under five years old.</p><p>The company said it has already started a pivotal pediatric phase 3 trial evaluating the vaccine in up to 2,400 healthy children.</p><p>Pfizer said it plans to move directly to a fifth-generation adult pneumococcal vaccine candidate covering 35 serotypes, which it expects to enter clinical development by the end of 2026.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pfizer Says Next-Generation Pneumococcal Vaccine Showed Stronger Immune Response in Infant Study</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPfizer Says Next-Generation Pneumococcal Vaccine Showed Stronger Immune Response in Infant Study\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-05-20 17:37</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Pfizer (PFE) said Wednesday that its experimental 25-valent pneumococcal vaccine generated stronger immune responses than the company's currently approved PREVNAR 20 in a mid-stage infant study.</p><p>Preliminary phase 2 data showed antibody levels against serotype 3, a major remaining cause of pneumococcal disease in children, were significantly higher in infants receiving Pfizer's investigational vaccine candidate, 25vPnC, compared with Prevnar 20 after both the third and fourth doses, Pfizer said.</p><p>Pfizer said the vaccine candidate could potentially cover up to 90% of disease-causing pneumococcal serotypes in children under five years old.</p><p>The company said it has already started a pivotal pediatric phase 3 trial evaluating the vaccine in up to 2,400 healthy children.</p><p>Pfizer said it plans to move directly to a fifth-generation adult pneumococcal vaccine candidate covering 35 serotypes, which it expects to enter clinical development by the end of 2026.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4568","symbol_name":"美国抗疫概念","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2636810748","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2636810748","pubTimestamp":1779269874,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Pfizer  said Wednesday that its experimental 25-valent pneumococcal vaccine generated stronger immune responses than the company's currently approved PREVNAR 20 in a mid-stage infant study.Preliminary phase 2 data showed antibody levels against serotype 3, a major remaining cause of pneumococcal disease in children, were significantly higher in infants receiving Pfizer's investigational vaccine candidate, 25vPnC, compared with Prevnar 20 after both the third and fourth doses, Pfizer said.Pfizer said the vaccine candidate could potentially cover up to 90% of disease-causing pneumococcal serotypes in children under five years old.The company said it has already started a pivotal pediatric phase 3 trial evaluating the vaccine in up to 2,400 healthy children.Pfizer said it plans to move directly to a fifth-generation adult pneumococcal vaccine candidate covering 35 serotypes, which it expects to enter clinical development by the end of 2026.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4568":"美国抗疫概念","LU0456855351.SGD":"JPMorgan Funds - Global Equity A (acc) SGD","BK4588":"碎股","BK4550":"红杉资本持仓","LU0058720904.USD":"联博国际健康护理基金A","LU1057294990.SGD":"Blackrock World Healthscience A2 SGD-H","PFE":"辉瑞","LU1894683264.USD":"AMUNDI FUNDS US EQUITY RESEARCH VALUE \"A2\" (USD) ACC","LU0122379950.USD":"贝莱德世界健康科学A2","LU0306807586.USD":"SCHRODER ISF GLOBAL DIVIDEND MAXIMISER \"A\" (USD) INC QF","BK4007":"制药","SG9999001176.USD":"United Global Healthcare Acc USD","LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","LU1066051498.USD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM2\" (USD) INC","LU0321505868.SGD":"Schroder ISF Global Dividend Maximiser A Dis SGD","LU1066053197.SGD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM3\" (SGDHDG) INC","IE00BLSP4239.USD":"Legg Mason ClearBridge - Tactical Dividend Income A Mdis USD Plus","BK4581":"高盛持仓","BK4599":"减肥药","SG9999002224.SGD":"Allianz Global High Payout SGD","LU0170899867.USD":"EASTSPRING INVESTMENTS WORLD VALUE EQUITY  \"A\" (USD) ACC","LU0306806265.USD":"SCHRODER ISF GLOBAL DIVIDEND MAXIMISER \"A\" ACC","LU1883839398.USD":"AMUNDI FUNDS INCOME OPPORTUNITIES \"A2\" (USD) ACC","LU0225771236.USD":"SCHRODER ISF GLOBAL EQUITY YIELD \"A\" (USD) INC MF","BK4585":"ETF&股票定投概念","IE00B19Z3581.USD":"Legg Mason ClearBridge - Value A Acc USD","BK4534":"瑞士信贷持仓","LU1023059063.AUD":"BGF WORLD HEALTHSCIENCE \"A2\" (AUDHDG) ACC","BK4533":"AQR资本管理(全球第二大对冲基金)","IE00B3T34201.USD":"BNY MELLON GLOBAL EQUITY INCOME \"B\" (USD) INC","BK7095":"多种金属与采矿","IE00BLSP4452.SGD":"Legg Mason ClearBridge - Tactical Dividend Income A Mdis SGD-H Plus","SG9999002232.USD":"Allianz Global High Payout USD","IE00B19Z3B42.SGD":"Legg Mason ClearBridge - Value A Acc SGD","SG9999011175.SGD":"Nikko AM Global Dividend Equity Dis SGD-H","LU1894683348.USD":"AMUNDI FUNDS US EQUITY RESEARCH VALUE \"A2\" (USD) INC","SG9999013999.USD":"UOB UNITED GLOBAL HEALTHCARE FUND (USDHDG) INC","IE00BBT3K403.USD":"LEGG MASON CLEARBRIDGE TACTICAL DIVIDEND INCOME \"A(USD) ACC","SG9999003800.SGD":"Nikko AM Global Dividend Equity Acc SGD-H","IE0002270589.USD":"LEGG MASON CLEARBRIDGE VALUE \"A\" (USD) INC","LU0321505439.SGD":"Schroder ISF Global Dividend Maximiser A Acc SGD","BK4592":"伊斯兰概念","SG9999001176.SGD":"UOB UNITED GLOBAL HEALTHCARE \"SGD\" (ACC)","SGXZ57979304.SGD":"United Global Healthcare A Acc SGD-H","LU0234572021.USD":"高盛美国核心股票组合Acc","IE000M9KFDE8.USD":"NEUBERGER BERMAN US LARGE CAP VALUE \"A\" (USD) ACC","LU0868494617.USD":"UBS (LUX) EQUITY SICAV - US TOTAL YIELD SUSTAINABLE \"P\" (USD) ACC","LU0985481810.HKD":"SCHRODER ISF GLOBAL EQUITY YIELD \"A\" (HKD) INC M","LU0225284248.USD":"SCHRODER ISF GLOBAL EQUITY YIELD \"A\" ACC"},"translate_title":"辉瑞称下一代肺炎球菌疫苗在婴儿研究中显示出更强的免疫反应","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PFE":1.98},"content_text":"Pfizer (PFE) said Wednesday that its experimental 25-valent pneumococcal vaccine generated stronger immune responses than the company's currently approved PREVNAR 20 in a mid-stage infant study.Preliminary phase 2 data showed antibody levels against serotype 3, a major remaining cause of pneumococcal disease in children, were significantly higher in infants receiving Pfizer's investigational vaccine candidate, 25vPnC, compared with Prevnar 20 after both the third and fourth doses, Pfizer said.Pfizer said the vaccine candidate could potentially cover up to 90% of disease-causing pneumococcal serotypes in children under five years old.The company said it has already started a pivotal pediatric phase 3 trial evaluating the vaccine in up to 2,400 healthy children.Pfizer said it plans to move directly to a fifth-generation adult pneumococcal vaccine candidate covering 35 serotypes, which it expects to enter clinical development by the end of 2026.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2636810748","isCrawlerRequest":true}